Skip to main content

Table 8 Parameters for evaluating the anti-amastigote activity of larval products on J774A.1 macrophages infected with Leishmania major

From: The therapeutic effect of larval saliva and hemolymph of Lucilia sericata on the treatment of Leishmania major lesion in BALB/c mice946

Treatment

Dosages (ug/ml)

PL

SVI

120 h

72 h

120 h

72 h

No treatment control

0

2.86 ± 0.89

2.05 ± 0.71

175.3 ± 9.3

97.8 ± 8.1

Saliva

150

2.09 ± 0.58

1.98 ± 0.69

106.6 ± 7.81

61.38 ± 5.9

450

1.90 ± 0.33

1.81 ± 0.43

78.00 ± 6.8

42.29 ± 4.3

Hemolymph

150

1.85 ± 0.53

1.77 ± 0.60

87.00 ± 8.1

47.16 ± 6.7

450

1.76 ± 0.42

1.69 ± 0.32

52.47 ± 3.8

17.74 ± 2.4

Positive control glucantime

50

1.92 ± 0.51

1.72 ± 0.38

84.21 ± 5.7

38.85 ± 4.5

100

1.69 ± 0.34

1.45 ± 0.31

53.78 ± 3.5

18.82 ± 1.1

  1. PL parasite load, SVI survival index